Juno Therapeutics, Inc. (NASDAQ:JUNO) saw a large drop in short interest in September. As of September 29th, there was short interest totalling 9,481,474 shares, a drop of 29.9% from the September 15th total of 13,519,026 shares. Based on an average trading volume of 2,962,349 shares, the short-interest ratio is presently 3.2 days. Currently, 11.2% of the company’s stock are sold short.
A number of analysts recently commented on JUNO shares. Morgan Stanley reiterated an “equal weight” rating and issued a $43.00 target price (up from $27.00) on shares of Juno Therapeutics in a report on Friday, October 6th. Vetr raised shares of Juno Therapeutics from a “strong sell” rating to a “sell” rating and set a $25.50 price objective on the stock in a research report on Monday, August 14th. Zacks Investment Research downgraded shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 28th. Raymond James Financial, Inc. upgraded shares of Juno Therapeutics from a “market perform” rating to an “outperform” rating and set a $45.00 target price for the company in a research note on Tuesday, August 29th. Finally, Barclays PLC assumed coverage on shares of Juno Therapeutics in a research note on Wednesday, September 6th. They issued an “overweight” rating and a $55.00 target price for the company. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $38.64.
Shares of Juno Therapeutics (JUNO) opened at 43.53 on Friday. The firm’s 50-day moving average is $43.60 and its 200-day moving average is $31.48. Juno Therapeutics has a one year low of $17.52 and a one year high of $47.03. The company’s market cap is $4.57 billion.
Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The company had revenue of $21.30 million for the quarter, compared to analysts’ expectations of $15.59 million. During the same quarter in the previous year, the firm posted ($0.64) EPS. The firm’s quarterly revenue was down 22.8% compared to the same quarter last year. Analysts expect that Juno Therapeutics will post ($3.08) EPS for the current fiscal year.
In related news, insider Sunil Agarwal sold 7,285 shares of Juno Therapeutics stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $44.76, for a total value of $326,076.60. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Richard Klausner sold 12,000 shares of Juno Therapeutics stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $30.34, for a total transaction of $364,080.00. Following the completion of the sale, the director now owns 788,985 shares in the company, valued at $23,937,804.90. The disclosure for this sale can be found here. Insiders sold a total of 85,004 shares of company stock valued at $3,551,561 over the last ninety days. Company insiders own 15.26% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company grew its holdings in shares of Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 228 shares during the period. Pacad Investment Ltd. bought a new stake in Juno Therapeutics during the second quarter valued at about $105,000. QS Investors LLC bought a new stake in Juno Therapeutics during the second quarter valued at about $135,000. Macquarie Group Ltd. bought a new stake in Juno Therapeutics during the second quarter valued at about $248,000. Finally, Great West Life Assurance Co. Can grew its holdings in Juno Therapeutics by 80.5% during the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 3,800 shares during the period. 67.50% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Juno Therapeutics, Inc. (NASDAQ:JUNO) Short Interest Update” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/10/27/short-interest-in-juno-therapeutics-inc-juno-drops-by-29-9.html.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.